enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline, a muscarinic agonist; and trospium chloride, a muscarinic antagonist. [1] Xanomeline is a functionally preferring muscarinic M 4 and M 1 receptor agonist. [1]

3. FDA approves 1st new drug for schizophrenia in more ... - AOL

   www.aol.com/fda-approves-1st-drug-schizophrenia...

   Cobenfy, manufactured by Bristol Myers Squibb, combines two drugs, xanomeline and trospium chloride, and is taken as a twice-daily pill. In clinical trials, this combination helped manage symptoms ...

4. Xanomeline - Wikipedia

   en.wikipedia.org/wiki/Xanomeline

   Xanomeline/trospium, sold under the brand name Cobenfy, is an approved combination drug used in the treatment of schizophrenia. [ 6 ] [ 7 ] Trospium chloride is a peripherally selective non-selective muscarinic antagonist to quell peripheral muscarinic agonist-dependent side effects.

5. Management of schizophrenia - Wikipedia

   en.wikipedia.org/wiki/Management_of_schizophrenia

   The fixed-dose combination medication xanomeline/trospium chloride (Cobenfy) was approved for medical use in the United States in September 2024. [ 29 ] [ 30 ] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors ...

6. Bristol Myers wins US FDA approval for new type of ...

   www.aol.com/news/us-fda-approves-bristol-myers...

   William Blair analysts expect $2.5 billion in U.S. sales for Cobenfy by 2030. Bristol said it expects to make the drug available to patients by late October at a list price of $1,850 a month or ...

7. This FDA-approved drug promises a new way to treat ... - AOL

   www.aol.com/fda-approved-drug-promises-way...

   KarXT is a twice-daily oral medication for adults that combines two drugs: Xanomeline, which targets muscarinic receptors in the brain, and trospium, which alleviates digestive and other symptoms ...

8. FDA Approves the First New Schizophrenia Drug in Decades - AOL

   www.aol.com/lifestyle/fda-approves-first...

   The medicine works in an entirely different way from existing treatments.

9. Muscarinic agonist - Wikipedia

   en.wikipedia.org/wiki/Muscarinic_agonist

   The dual M1, M4 agonist xanomeline has been proposed as a potential treatment for schizophrenia. [5] [6] Xanomeline/trospium chloride was approved in the US in 2024. [7] Based on preclinical pharmacological and genetic studies, M1 predominantly modulates cognitive symptom domains and modestly regulates psychosis symptom domains. [8]